莫塞妥莫单抗帕苏多毒素治疗复发/难治性毛细胞白血病
这项关键性、多中心、开放标签研究评估了靶向CD22的重组免疫毒素莫塞妥莫单抗帕苏多毒素治疗复发/难治性毛细胞白血病。80例既往接受过≥2种系统治疗(包括≥1种嘌呤核苷类似物)的患者接受40 µg/kg静脉给药,每28天第1、3、5天给药,最多6个周期。持久完全缓解率为30%,完全缓解率为41%,客观缓解率为75%,完全缓解者中85%达到微小残留病变阴性。
要点
- 持久完全缓解率为30%,完全缓解率为41%,客观缓解率为75%。
- 64例(80%)患者达到血液学缓解,完全缓解者中27例(85%)微小残留病变阴性。
- 治疗相关严重不良事件包括溶血性尿毒症综合征(7.5%)和毛细血管渗漏综合征(5%),可逆且一般可通过支持治疗和停药处理。
核心结论
- 莫塞妥莫单抗帕苏多毒素治疗经重度治疗的毛细胞白血病患者,获得高比例的独立评估持久缓解和微小残留病变清除,耐受性可接受。
研究设计与样本
- 关键性、多中心、开放标签研究,纳入80例既往接受≥2种系统治疗(包括≥1种嘌呤核苷类似物)的复发/难治性毛细胞白血病患者。
- 患者接受莫塞妥莫单抗帕苏多毒素40 µg/kg静脉给药,每28天第1、3、5天给药,最多6个周期。
- 由盲法独立中心审查确定疾病缓解和微小残留病变状态。
主要发现
- 80例患者中(79%为男性;中位年龄60.0岁),持久完全缓解率为30%,完全缓解率为41%,客观缓解率(完全缓解和部分缓解)为75%。
- 64例患者(80%)达到血液学缓解。
- 完全缓解者中27例(85%)通过免疫组织化学达到微小残留病变阴性。
- 最常见的不良事件为外周水肿(39%)、恶心(35%)、乏力(34%)和头痛(33%)。
- 治疗相关严重不良事件溶血性尿毒症综合征(7.5%)和毛细血管渗漏综合征(5%)为可逆性,一般可通过支持治疗和停药处理(6例患者;7.5%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/refractory HCL who had ≥2 prior systemic therapies, including ≥1 purine nucleoside analog. Patients received moxetumomab pasudotox 40 µg/kg intravenously on days 1, 3, and 5 every 28 days for ≤6 cycles. Blinded independent central review determined disease response and minimal residual disease (MRD) status. Among 80 patients (79% males; median age, 60.0 years), durable complete response (CR) rate was 30%, CR rate was 41%, and objective response rate (CR and partial response) was 75%; 64 patients (80%) achieved hematologic remission. Among complete responders, 27 (85%) achieved MRD negativity by immunohistochemistry. The most frequent adverse events (AEs) were peripheral edema (39%), nausea (35%), fatigue (34%), and headache (33%). Treatment-related serious AEs of hemolytic uremic syndrome (7.5%) and capillary leak syndrome (5%) were reversible and generally manageable with supportive care and treatment discontinuation (6 patients; 7.5%). Moxetumomab pasudotox treatment achieved a high rate of independently assessed durable response and MRD eradication in heavily pretreated patients with HCL, with acceptable tolerability.
引用
- Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018. PMID: 30030507. doi:10.1038/s41375-018-0210-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。